BACKGROUND: Radiofrequency Ablation is the most widely performed percutaneous treatment for Hepatocellular Carcinoma. This multicentre study was aimed at assessing the complication, overall survival and disease-free survival rates in cirrhotic patients with single Hepatocellular Carcinoma nodule ≤3 cm undergoing Radiofrequency Ablation. METHODS: Data of 365 patients (59% males; mean age 67 ± 8 years), Child-Pugh A/B, with single Hepatocellular Carcinoma nodule ≤3 cm (tumours >2-3 cm = 127/236), showing complete necrosis after Radiofrequency Ablation between 1998 and 2010 in 7 Italian Centers were retrospectively reviewed. Complication, overall survival and disease-free survival rates were analyzed as main clinical end-points. RESULTS: Major complications were observed in 8 patients (2.2%) and minor complications in 23 patients (6.3%). The 3-, and 5-year overall survival rates were 80% and 64%. One hundred and seven patients (29.5%) died, being 41 deaths (38.3%) Hepatocellular Carcinoma-related. At multivariate analysis only age (p = 0.04; OR 2.29), ascites (p < 0.001; OR 3.74) and Child-Pugh class ≥B8 (p = 0.003; OR 2.42) were confirmed as independent predictors for overall survival. The disease-free survival rates at 3- and 5-year were 50%, and 41.8%. CONCLUSIONS: Radiofrequency Ablation is an effective and safe tool for the treatment of single Hepatocellular Carcinoma ≤3 cm providing excellent 5-year overall survival and disease-free survival rates. Patient's age and liver status appeared as main determinants of outcome.
BACKGROUND: Radiofrequency Ablation is the most widely performed percutaneous treatment for Hepatocellular Carcinoma. This multicentre study was aimed at assessing the complication, overall survival and disease-free survival rates in cirrhotic patients with single Hepatocellular Carcinoma nodule ≤3 cm undergoing Radiofrequency Ablation. METHODS: Data of 365 patients (59% males; mean age 67 ± 8 years), Child-Pugh A/B, with single Hepatocellular Carcinoma nodule ≤3 cm (tumours >2-3 cm = 127/236), showing complete necrosis after Radiofrequency Ablation between 1998 and 2010 in 7 Italian Centers were retrospectively reviewed. Complication, overall survival and disease-free survival rates were analyzed as main clinical end-points. RESULTS: Major complications were observed in 8 patients (2.2%) and minor complications in 23 patients (6.3%). The 3-, and 5-year overall survival rates were 80% and 64%. One hundred and seven patients (29.5%) died, being 41 deaths (38.3%) Hepatocellular Carcinoma-related. At multivariate analysis only age (p = 0.04; OR 2.29), ascites (p < 0.001; OR 3.74) and Child-Pugh class ≥B8 (p = 0.003; OR 2.42) were confirmed as independent predictors for overall survival. The disease-free survival rates at 3- and 5-year were 50%, and 41.8%. CONCLUSIONS: Radiofrequency Ablation is an effective and safe tool for the treatment of single Hepatocellular Carcinoma ≤3 cm providing excellent 5-year overall survival and disease-free survival rates. Patient's age and liver status appeared as main determinants of outcome.
Authors: Iswanto Sucandy; Susannah Cheek; Benjamin J Golas; Allan Tsung; David A Geller; James W Marsh Journal: HPB (Oxford) Date: 2016-07-09 Impact factor: 3.647
Authors: Al B Benson; Michael I D'Angelica; Daniel E Abbott; Thomas A Abrams; Steven R Alberts; Daniel Anaya Saenz; Chandrakanth Are; Daniel B Brown; Daniel T Chang; Anne M Covey; William Hawkins; Renuka Iyer; Rojymon Jacob; Andrea Karachristos; R Kate Kelley; Robin Kim; Manisha Palta; James O Park; Vaibhav Sahai; Tracey Schefter; Carl Schmidt; Jason K Sicklick; Gagandeep Singh; Davendra Sohal; Stacey Stein; G Gary Tian; Jean-Nicolas Vauthey; Alan P Venook; Andrew X Zhu; Karin G Hoffmann; Susan Darlow Journal: J Natl Compr Canc Netw Date: 2017-05 Impact factor: 11.908
Authors: Muneeb Ahmed; Luigi Solbiati; Christopher L Brace; David J Breen; Matthew R Callstrom; J William Charboneau; Min-Hua Chen; Byung Ihn Choi; Thierry de Baère; Gerald D Dodd; Damian E Dupuy; Debra A Gervais; David Gianfelice; Alice R Gillams; Fred T Lee; Edward Leen; Riccardo Lencioni; Peter J Littrup; Tito Livraghi; David S Lu; John P McGahan; Maria Franca Meloni; Boris Nikolic; Philippe L Pereira; Ping Liang; Hyunchul Rhim; Steven C Rose; Riad Salem; Constantinos T Sofocleous; Stephen B Solomon; Michael C Soulen; Masatoshi Tanaka; Thomas J Vogl; Bradford J Wood; S Nahum Goldberg Journal: J Vasc Interv Radiol Date: 2014-10-23 Impact factor: 3.464